Certolizumab pegol, a monthly subcutaneously administered Fc-free anti-TNF alpha, improves health-related quality of life in patients with moderate to severe Crohn's disease
Rutgeerts, Paul × Schreiber, Stefan Feagan, Brian Keininger, Dorothy L O'Neil, Liz Fedorak, Richard N #
International Journal of Colorectal Disease vol:23 issue:3 pages:289-296
Background and aims Certolizumab pegol, a polyethylene glycolated Fc-free Fab' was efficacious and well tolerated in patients with moderate-to-severe Crohn's disease in a previously reported randomized, placebo-controlled study. In this paper, we report the effect of certolizumab pegol on health-related quality of life (HRQoL).